All In Biotech

Drug Trial Radar · NCT02484547

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Sep 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,643 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,643

Actual

Start

Sep 15, 2015

Primary completion

Aug 5, 2019

Study completion Aug 5, 2019

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jun 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) \[ADAS-Cog 13\], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) \[ADCS-ADL-MCI\].

Conditions

  • Alzheimer's Disease

Interventions

  • Aducanumab (BIIB037)Drug

    Low dose

  • Aducanumab (BIIB037)Drug

    High dose

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78Time frame: Baseline, Week 78

Locations

180 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner Alzheimer's Institute

    Phoenix, Arizona

  • Xenoscience Inc.

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Institute for Memory Impairments

    Irvine, California

  • Renewal Behavioral Health

    Long Beach, California

  • USC Keck School of Medicine

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Excell Research, Inc.

    Oceanside, California

  • Pacific Neuroscience Medical Group

    Oxnard, California

  • Anderson Clinical Research

    Redlands, California

  • Pacific Research Network

    San Diego, California

  • University of California San Diego Medical Center

    San Diego, California

  • California Pacific Medical Center

    San Francisco, California

  • Syrentis Clinical Research

    Santa Ana, California

  • St Joseph Heritage Healthcare

    Santa Rosa, California

  • Stanford University Medical Center

    Stanford, California

  • University Of Colorado Denver

    Aurora, Colorado

  • IMMUNOe International Research Centers

    Thornton, Colorado

  • Associated Neurologists of Southern Connecticut, PC

    Fairfield, Connecticut

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Research Center for Clinical Studies, Inc.

    Norwalk, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • Bradenton Research Center, Inc.

    Bradenton, Florida

  • Meridien Research

    Brooksville, Florida

  • Quantum Laboratories Inc.

    Deerfield Beach, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • Emory University Cognitive Neurology Clinic & ADRC

    Atlanta, Georgia

  • Medical Research Health and Education Foundation, Inc

    Columbus, Georgia

  • NeuroStudies.net, LLC

    Decatur, Georgia

  • Josephson, Wallack, Munshower Neurology, PC

    Indianapolis, Indiana

  • McLean Hospital

    Belmont, Massachusetts

  • Boston Center for Memory

    Newton, Massachusetts

  • Hattiesburg Clinic, PA

    Hattiesburg, Mississippi

  • Cleveland Clinic Lou Ruvo Center for Brain Health

    Las Vegas, Nevada

  • ActivMed Practices & Research

    Portsmouth, New Hampshire

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.